Immunofluorescence data indicated that the expression of GM-CSF was increased in subcutaneous tumors with naïve MSCs compared to the control group (i.e., GBM), while no statistically significant changes were found in tumors with MSCMel (Figure S6K). This evidence concerns the gene CSF2 and glioblastoma.